Your Employer Is Deciding Whether to Keep Covering Your GLP-1

The Decision Is Being Made This Quarter

If you take a GLP-1 for weight management and your employer covers it, that coverage is being reviewed right now. Benefits teams finalize plan design for the following year over the summer. By the time open enrollment materials hit your inbox in October, the call has already been made.

Here is where things stand. A Business Group on Health survey fielded in February and March found that 67 percent of large employers currently cover GLP-1s for weight loss. Only 72 percent of those said they were likely to maintain that coverage in 2027. Roughly one in ten employers offering it today do not expect to offer it next year.

Mercer's read is somewhat narrower, with about 5 percent of employers over 500 people planning to eliminate the benefit outright. Either way you are looking at a meaningful slice of covered people losing coverage on a drug they are actively taking.

Nobody is going to call you about it.

Why Employers Are Backing Away

It helps to see the number they are looking at, because it explains the behavior better than any statement about wellness priorities.

GLP-1s accounted for 11.4 percent of annual claims in 2026, up from 6.9 percent in 2023. One drug class, more than a tenth of everything a plan pays out, and the share nearly doubled in three years. Almost 8 in 10 employers say these drugs are driving up their health care costs.

The uncomfortable part is that this is a cost problem created by the drugs working. Unlike a specialty drug for a rare condition, the eligible population here is enormous. When a benefits director models what happens if even a quarter of eligible employees start a medication costing over $1,000 a month with no defined endpoint, the projection breaks the budget. So they look for a lever.

I am not defending the outcome. But if you want to predict what your plan does next year, understanding that the math is genuinely brutal is more useful than assuming somebody is being cheap.

The Insurers Already Moved

This is not a forecast. It started in January.

Blue Cross Blue Shield of Massachusetts dropped GLP-1 coverage for obesity treatment for employers with fewer than 100 employees at the beginning of 2026. Harvard Pilgrim Health Care dropped weight-loss GLP-1 coverage. So did Blue Cross Blue Shield of Michigan.

Notice the pattern in the first one. Small employers first. A 40-person company does not have the leverage to negotiate a carve-out and does not have enough covered lives to spread the risk. If you work somewhere small, you are the most exposed and you will likely be the last to hear.

The Distinction That Decides Your Case

Coverage for these drugs splits along a line most people do not know exists, and it is worth learning before you call anyone.

Plans distinguish between the diabetes indication and the weight management indication. Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy and Zepbound are the same underlying compounds approved for weight management. When an employer drops GLP-1 coverage, they are almost always dropping the weight management indication. Diabetes coverage generally stays, because dropping a diabetes drug is a different conversation with a different legal profile.

So the question to ask your HR department is not whether the plan covers Wegovy. It is whether the plan covers GLP-1s for weight management in 2027, and whether there is an exception pathway for cardiovascular indications. Wegovy carries an approval for reducing cardiovascular risk in certain patients with established heart disease, and some plans that drop weight-loss coverage keep that pathway open. If you have a cardiac history, that distinction may be worth several thousand dollars a year to you.

What It Costs When Coverage Goes Away

List prices on these drugs run north of $1,000 a month, which is the number that gets quoted and is not the number most uninsured patients pay.

Both manufacturers now run direct-to-patient self-pay programs, and those have brought cash prices down substantially, into the several-hundred-dollars-a-month range depending on the drug and the dose. That is a real option and you should price it before assuming you are done. It is also, for most households, still an enormous recurring expense. Call it a car payment that does not build equity.

A few things that genuinely help. Your HSA or FSA can pay for these with pre-tax dollars if you have a prescription, which effectively knocks your marginal tax rate off the price. If you are in the 22 percent bracket, a $500 monthly cost becomes closer to $390. That is the single largest lever available to most people and it is badly underused, which is a recurring theme with health savings accounts generally.

Manufacturer savings cards exist but are typically restricted to people with commercial insurance that covers the drug, which excludes exactly the people who need them once coverage drops. Read the eligibility language before you count on it.

The Prior Authorization Maze Is the More Likely Outcome

Outright elimination gets the headlines. The far more common move is to keep coverage and make it harder to use, and this is what most people will actually run into.

Expect some combination of a BMI threshold, a documented comorbidity requirement, mandatory enrollment in a lifestyle or coaching program, step therapy requiring you to fail a cheaper drug first, and annual reauthorization. Each one is defensible in isolation. Stacked, they function as a filter, and the attrition is the point.

If you get denied, appeal. Insurers count on you not appealing, and a meaningful share of denials get overturned when a physician submits documentation. Ask your prescriber's office whether they have someone who handles prior authorizations, because most practices do and that person is far better at this than you will be. Get the denial reason in writing, because the appeal has to address the specific reason given rather than the general merits of the drug.

And if your plan is self-funded, which most large employer plans are, your appeal goes to your employer's plan administrator rather than to a state insurance regulator. That changes who you are actually persuading, and it is worth knowing which situation you are in before you write the letter.

What to Do Before Open Enrollment

Ask HR directly, in writing, whether GLP-1 coverage for weight management is changing for 2027. Email, not a hallway conversation. You want a record and you want an answer before the enrollment window rather than during it.

If the answer is yes it is changing, or if nobody will tell you, find out what a 90-day supply costs and whether your prescriber can write one before the plan year turns over. Filling a longer supply under current coverage is the most straightforward thing you can do with the time you have.

Then look at whether a spouse's plan covers it. Plans differ enormously on this specific drug class right now, and it has become a genuine reason to move a family onto the other employer's coverage. That comparison used to be about networks and deductibles. This year, for a lot of households, it comes down to one line on the formulary.